Metagenomi (MGX) Projected to Post Quarterly Earnings on Monday

Metagenomi (NASDAQ:MGX) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 3:00 PM ET.

Metagenomi (NASDAQ:MGX) last released its earnings results on Thursday, March 5th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). Metagenomi had a negative net margin of 348.54% and a negative return on equity of 47.14%. The company had revenue of $3.91 million during the quarter, compared to analyst estimates of $7.33 million. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Metagenomi Stock Performance

Shares of NASDAQ MGX opened at $1.46 on Friday. The stock has a 50 day moving average price of $1.59 and a 200 day moving average price of $1.92. Metagenomi has a 52 week low of $1.23 and a 52 week high of $3.95. The stock has a market capitalization of $54.93 million, a PE ratio of -0.62 and a beta of 0.45.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Metagenomi in a research note on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Institutional Investors Weigh In On Metagenomi

Several hedge funds have recently bought and sold shares of MGX. Bank of America Corp DE grew its holdings in Metagenomi by 482.9% during the fourth quarter. Bank of America Corp DE now owns 21,113 shares of the company’s stock worth $76,000 after purchasing an additional 17,491 shares during the period. AQR Capital Management LLC bought a new stake in Metagenomi in the first quarter valued at approximately $119,000. Norges Bank acquired a new stake in shares of Metagenomi in the second quarter valued at approximately $373,000. Marshall Wace LLP acquired a new stake in shares of Metagenomi in the second quarter valued at approximately $222,000. Finally, Jane Street Group LLC bought a new position in shares of Metagenomi during the 2nd quarter worth approximately $235,000.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.